

# **Antitrust + Competition Life Sciences Quarterly Update Q1 2022**



Despite the aggressive rhetoric, the change in the leadership and composition at the U.S. Federal Trade Commission (FTC) did not result in more enforcement in 2021. As the calendar turned to 2022, the FTC seems to be stepping up its enforcement track record in the life sciences sector. Antitrust + Competition lawyers [Arman Oruc](#), [Andrew Lacy](#), [Sarah Jordan](#) and [Elliot Silver](#) discuss how the changes at the FTC have affected life sciences companies in the [Antitrust + Competition Life Sciences Quarterly Update](#).